Test drugs on the patient's own cancer cells when there is no trial to join
For very rare cancers there is often no genetic clue and no trial. Growing the patient's cells and testing drugs on them directly can suggest what to try.
Functional precision medicine — ex vivo drug sensitivity testing on fresh patient material — guided treatment with reported benefit in a randomised haematology study and in paediatric and rare solid tumour case series. Turnaround, tissue quality and the absence of standardised reporting are the barriers. For rare cancers where genomics is uninformative, function is the only remaining evidence source.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
- Preclinical models that do not predict people · Nine in ten cancer drugs that work in mice fail in humans. Our models are the reason.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Pages like this
not linked directly; found by shared links- IdeaHold organoid drug tests to the same standard as a diagnostic test
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
- IdeaRun the mouse or organoid trial at the same time as the human trial
Shares Champions Oncology, Xilis, Patient-derived xenografts, Functional (ex vivo) drug testing.
- TechnologyOrganoid-guided therapy at scale
Shares Curesponse, SEngine Precision Medicine, Xilis, Patient-derived xenografts.
- IdeaGrow each trial patient's tumour as organoids to decide which platform arm opens next
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
- IdeaAn open model bank for the rare tumours nobody has models for
Shares Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaAn open organoid bank for cancers too rare to have models
Shares Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people, Biliary tract cancer (cholangiocarcinoma).
- IdeaTest drugs on freshly cut slices of the patient's own tumour
Shares Curesponse, Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaHumanised mice with an immune system matched to the tumour donor
Shares Champions Oncology, Patient-derived xenografts, Preclinical models that do not predict people.